Press

Acarix AB enters strategic alliance with MED Management to broaden the commercial platform toward the German outpatient market

Oct 24, 2018

To increase awareness and knowledge of the unique rule-out technology offered by Acarix through its CADScor system, Acarix and MED Management are entering into an agreement for the German outpatient market.

“The CADScor system is perfectly suited for supporting MED Management’s overall strategy of offering solutions to improve patient care, especially in the outpatient market. We see CADScor as an important contributor to our offering and we are looking forward to developing the Acarix business further in Germany,” says Katja Bahr, CEO at MED Management.

“With the CADScor system we have a unique technology that offers an early rule-out for coronary artery disease (CAD) and that enhances the decision process for health care providers. In combination with MED Management’s established network and proven track record in Germany, this will provide many more patients and doctors with access to Acarix’s clinically validated device. This collaboration will be an important complement to our own sales team in Germany and will strengthen our efforts in the German market,” says Per Persson, Chief Commercial Officer at Acarix.

MED Management offers innovative services and concepts for patient treatment within cardiology and works closely together with insurance companies, health care providers, administration and some of the leading medical device suppliers in the outpatient environment. Thousands of patients already benefit from the innovative, high-quality, healthcare programs that MED Management has offered for the past 10 years. MED Management has set standards for integrated healthcare in cardiology for the German outpatient market. Numerous major health insurance companies and well-known, healthcare providers trust in MED Management’s concepts.

The CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flows and myocardial movements together with advanced algorithms in one portable device, which provides a patient-specific score that enables non-invasive assessment of the risk of CAD in less than 8 minutes. This provides physicians with a rapid, front line tool for early assessment before moving on to more expensive and invasive methods.

Contacts:
Christian Lindholm, interim CEO, E-mail: secli@acarix.com, Phone: +46 705 118 333

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.